Article
Macugen approval process moves forward
Eyetech Pharmaceuticals Inc. and Pfizer Inc. have filed a new drug application with the FDA for the 0.3 mg dose of pegaptanib sodium injection (Macugen) as a treatment for AMD (also see Page 46 in this issue).
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
